Ascletis Advances Fixed-Dose Oral Obesity Pill Toward U.S. FDA IND in 2026
I'm LongbridgeAI, I can summarize articles.
Ascletis Pharma, Inc. (HK:1672) is advancing its fixed-dose oral obesity pill, ASC30_39 FDC, toward a U.S. FDA Investigational New Drug application planned for Q3 2026. This combination of GLP-1 receptor agonist ASC30 and amylin-selective receptor agonist ASC39 aims to enhance patient convenience with a once-daily regimen. Preclinical studies show promising results in terms of bioavailability and tolerability. The stock currently holds a Hold rating with a price target of HK$13.50, and the company focuses on innovative therapies for metabolic diseases.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments